According to a new market research report titled, ‘Pharmaceutical
Automation Market by Component (Plant-level Controls, Enterprise-level
Controls, Plant Instrumentation), Mode of Automation (Semi-automatic, Fully
automatic), End User, and Geography - Global Forecast to 2029,’ the
pharmaceutical automation market is projected to reach $18.2 billion by 2029 at
a CAGR of 12.0% during the forecast period of 2022-2029.
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5280?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=12-12-2023
Increasing adoption of robots in pharmaceutical
manufacturing, government initiatives to promote industrial development, rising
investments for transforming conventional production facilities, and growing
demand for safe and digitized production processes are expected to support the
growth of this market during the forecast period.
The high initial cost of procuring automation hardware and
software is expected to restrain the growth of this market. Furthermore, the
growing demand for IIoT in pharmaceutical manufacturing and the huge demand for
vaccine manufacturing for COVID-19 are expected to offer significant growth
opportunities for players operating in this market. However, the limited
availability of skilled laborers and cybersecurity risks associated with
automated systems are major challenges for the growth of this market.
The Impact of COVID-19 on the Pharmaceutical Automation
Market
The outbreak of the COVID-19 pandemic increased the demand
for testing and production, resulting in an increased demand for automation
solutions. The pharma sector has transitioned from ad hoc automation
deployments to implementing robots as an important tool in the global battle
against COVID-19. The requirement for robot arms for viral DNA testing has
increased due to the COVID-19 pandemic. Furthermore, many pharmaceutical
companies have quickly adopted automation and robotics solutions for automated COVID-19
testing.
Pharmaceutical companies have effectively utilized the
advantages of automation to maintain or increase production without
compromising quality or safety. Automation has allowed pharmaceutical companies
to ramp up production safely and build production lines faster and in a more
scalable way. The COVID-19 pandemic has accelerated pre-existing trends, such
as flexible automation, digitalization, batch production, and personalization.
Speak to our Analysts to Understand the Impact of
COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5280?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=12-12-2023
The COVID-19 pandemic propelled the demand for SCARA and
collaborative robots for pharmaceutical manufacturing. Collaborative robots
have allowed pharmaceutical research companies to automate repetitive tasks,
and SCARA robots have enabled pharmaceutical companies to perform high-volume
tasks such as COVID-19 sample testing with greater accuracy.
The increasing demand for vaccines is expected to increase
the adoption of automation for pharmaceutical manufacturing. If the effects of
vaccination are short-term due to virus mutations, there will be an increase in
robotics adoption as more spending will be catered to automation and robotics
by the pharmaceutical industry.
The pharmaceutical automation market is segmented based on
component (enterprise-level controls [product lifecycle management, enterprise
resource planning, manufacturing execution systems], plant instrumentation
[motors & drives, robots, sensors, machine vision systems, relays &
switches, and other plant instrumentation components], plant-level controls
[supervisory control and data acquisition, distributed control systems,
programmable logic controllers, other plant-level controls]), mode of automation
(semi-automatic, fully-automatic), end user (pharmaceutical industry, biotech
industry), and geography. The study also evaluates industry competitors and
analyses the market at the regional and country levels.
Based on component, the pharmaceutical automation market is
segmented into enterprise-level controls, plant instrumentation, and
plant-level controls. In 2022, the enterprise-level controls segment is
estimated to account for the largest share of the pharmaceutical automation
market. The large market share of this segment is attributed to the benefits of
implementing product lifecycle management, enterprise resource planning, and
manufacturing execution systems solutions at the enterprise level. Manufacturing
execution systems solutions integrated with process control systems enable
pharmaceutical manufacturers to increase productivity and efficiency at a lower
cost and significantly reduce the time-to-market of new products. Furthermore,
these systems enable organizations to maintain and manage records of their
lifecycle, resulting in cost savings. However, the plant instrumentation
segment is expected to witness a significant growth rate during the forecast
period.
Quick Buy – “Pharmaceutical Automation Market by
Component (Plant-level Controls, Enterprise-level Controls, Plant
Instrumentation), Mode of Automation (Semi-automatic, Fully-automatic), End
User, and Geography - Global Forecast to 2029” Research Report: https://www.meticulousresearch.com/Checkout/87904065?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=12-12-2023
Based on mode of automation, the pharmaceutical automation
market is segmented into semi-automatic and fully-automatic systems. In 2022,
the semi-automatic segment is expected to account for the largest share of the
pharmaceutical automation market. However, the fully-automatic segment is
expected to register a higher CAGR during the forecast period. The rapid growth
of this segment is attributed to the increasing installation of complete
automation solutions in end-use industries such as chemicals & materials,
metals & mining, oil & gas, and paper & pulp. Fully-automatic
solutions aid the companies in these industries to efficiently manage
activities on-site and in offices.
Based on the end user, the pharmaceutical automation market
is segmented into pharmaceutical industry and biotech industry. In 2022, the
pharmaceutical industry segment is expected to account for the largest share of
the pharmaceutical automation market. The large market share of this segment is
attributed to the rapid adoption of continuous improvement process (CIP) to
improve production flexibility and efficiency and reduce wastage. Furthermore,
prominent technology players such as Microsoft, IBM, and Google are engaged in
developing automation and cloud solutions for the pharmaceutical and healthcare
industry to close security gaps and protect healthcare and pharmaceutical
production networks from external attacks.
Based on geography, Asia-Pacific is expected to account for
the largest share of the pharmaceutical automation market, followed by Europe
and North America. Asia-Pacific’s large market share is attributed to high
technical awareness regarding the usage of robotics in China, Japan, and
Singapore. The Asian pharmaceutical manufacturing sector has robust production
capabilities, which further fuels the demand for pharmaceutical automation
solutions in Asia-Pacific.
The major players operating in the pharmaceutical automation
market include ABB Group (Switzerland), Rockwell Automation (U.S.), Siemens AG
(Germany), Yaskawa Electric Corporation (Japan), Schneider Electric (France),
Yokogawa Electric Corporation (Japan), KUKA AG (Germany), Emerson Electric
(U.S.), Fanuc (Japan), Honeywell International (U.S.), Mitsubishi Electric
Corporation (Japan), OMRON Corporation (Japan), Advantech Co., Ltd. (Taiwan),
and Fuji Electric Co., Ltd. (Japan).
To gain more insights into the market with a detailed
table of content and figures, click here: https://www.meticulousresearch.com/product/pharmaceutical-automation-market-5280?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=12-12-2023
No comments:
Post a Comment